European Union Pharmaceutical Legislation
Source: PRA Health Sciences
In July 2012, a series of pharmaceutical legislation became effective in the European Union (EU), which included new requirements for Marketing Authorization Holders (MAH).
90-Day Reporting
Electronic 90-day-reporting of all non-serious adverse reactions occurring in the EU will become mandatory once full functionality of the EudraVigilance database is implemented (some Member States require 90-day reporting already). This means that ongoing processing of non-serious reports must take place, and companies can no longer have a large backlog of cases waiting to be processed in the hope for some “down time” to clear this.
access the Brochure!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.
Subscribe to Clinical Leader
X
Subscribe to Clinical Leader
This website uses cookies to ensure you get the best experience on our website. Learn more